SERB Pharmaceuticals

SERB Pharmaceuticals is a Belgium-based, global specialty pharma company with a dual focus on emergency medicine (antidotes/CBRN) and rare diseases. Founded in 2008 but tracing its heritage to the 1950s, SERB has built a fully integrated commercial platform, directly selling in 18 countries and supplying over 100. The company is in a clear growth phase, evidenced by strategic acquisitions like Y-mAbs Therapeutics, high-profile leadership appointments, and a pipeline leveraging its antibody platform, positioning it as a critical supplier to healthcare systems and governments worldwide.

Integrated end-to-end pharmaceutical development and commercialization platform, with a specialized antibody platform for novel antidote and therapeutic development.

In emergency medicine, SERB competes with a limited set of specialized pharma companies and government-backed manufacturers, holding a leading position in antidotes. In rare diseases, it faces competition from large biopharma companies and biotechs in niche oncology and neurology, where differentiation, pricing, and global commercial execution are key.